Heterozygous p53-deficient (+/-) mice develop fewer p53-negative preneoplastic focal liver lesions in response to treatment with diethylnitrosamine than do wild-type (+/+) mice

Cancer Letters

Volumn 207, Issue 2, 2004, Pages 149-155

  Finnberg, Niklas ^a   Stenius, Ulla ^a   Högberg, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Diethylnitrosamine; Heterozygous; p53; Preneoplastic lesions

Indexed keywords

DIETHYLNITROSAMINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENOTOXICITY; GENOTYPE; HETEROZYGOSITY; IMMUNOHISTOCHEMISTRY; LIVER INJURY; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DIETHYLNITROSAMINE; FEMALE; HETEROZYGOTE; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NUCLEAR PROTEINS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842609640     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.11.013     Document Type: Article

References (31)

1. Petzold G.L., Swenberg J.A. Detection of DNA damage induced in vivo following exposure of rats to carcinogens. Cancer Res. 38:1978;1589-1594.
2. Trzos R.J., Petzold G.L., Brunden M.N., Swenberg J.A. The evaluation of sixteen carcinogens in the rat using the micronucleus test. Mutat. Res. 58:1978;79-86.
3. Lindamood C. 3rd, Bedell M.A., Billings K.C., Dyroff M.C., Swenberg J.A. Swenberg Dose response for DNA alkylation, [3H]thymidine uptake into DNA, and O6-methylguanine-DNA methyltransferase activity in hepatocytes of rats and mice continuously exposed to dimethylnitrosamine. Cancer Res. 44:1984;196-200.
4. Deal F.H., Richardson F.C., Swenberg J.A. Dose response of hepatocyte replication in rats following continuous exposure to diethylnitrosamine. Cancer Res. 49:1989;6985-6988.
5. Bronstein S.M., Cochrane J.E., Craft T.R., Swenberg J.A., Skopek T.R. Toxicity, mutagenicity, and mutational spectra of N-ethyl-N-nitrosourea in human cell lines with different DNA repair phenotypes. Cancer Res. 51:1991;5188-5197.
6. Dyroff M.C., Richardson F.C., Popp J.A., Bedell M.A., Swenberg J.A. Correlation of O4-ethyldeoxythymidine accumulation, hepatic initiation and hepatocellular carcinoma induction in rats continuously administered diethylnitrosamine. Carcinogenesis. 7:1986;241-246.
7. Peto R., Gray R., Brantom P., Grasso P. Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study. Cancer Res. 51:1991;6415-6451.
8. Högberg J., Silins I., Finnberg N., Ståhl A., Stenius U. Attenuated p53 response to genotoxic stress in preneoplastic alterations in rat and mouse liver. Toxicol. Pathol. 29:2001;229-230.
9. Finnberg N., Stenius U., Högberg J. Xenobiotics modulate the p53 response to DNA damage in preneoplastic enzyme-altered foci in rat liver; effects of diethylnitrosamine and phenobarbital. Toxicol. Sci. 54:2000;95-103.
10. Lennartsson P., Högberg J., Stenius U. Wild-type p53 expression in liver tissue and in enzyme-altered foci: an in vivo investigation on diethylnitrosamine-treated rats. Carcinogenesis. 19:1998;1231-1237.
11. Van Gijssel H.E., Ohlson L.C., Torndal U.B., Mulder G.J., Eriksson L.C., Porsch-Hällstrom I., Meerman J.H. Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo. Hepatology. 32:2000;701-710.
12. Silins I., Finnberg N., Ståhl A., Högberg J., Stenius U. Reduced ATM kinase activity and an attenuated p53 response to DNA damage in carcinogen-induced preneoplastic hepatic lesions in the rat. Carcinogenesis. 22:2001;2023-2031.
13. Martens U., Stenius U. Immunohistochemical detection of induced expression of wild-type p53 tumor suppressor protein in the livers of rats treated with diethylnitrosamine. Histochem. J. 31:1999;75-78.
14. Thullberg M., Grasl-Kraupp B., Högberg J., Garberg P. Changes in liver fatty acid-binding protein in rat enzyme-altered foci. Cancer Lett. 128:1998;1-10.
15. Pugh T.D., King J.H., Koen H., Nychka D., Chover J., Wahba G., et al. Reliable stereological method for estimating the number of microscopic hepatocellular foci from their transections. Cancer Res. 43:1983;1261-1268.
16. van Gijssel H.E., Maassen C.B., Mulder G.J., Meerman J.H. p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumour promotion. Carcinogenesis. 18:1997;1027-1033.
17. Romach E.H., Goldsworthy T.L., Maronpot R.R., Fox T.R. Altered gene expression in spontaneous hepatocellular carcinomas from male B6C3F1 mice. Mol. Carcinog. 19:1997;31-38.
18. Santoni-Rugiu E., Jensen M.R., Thorgeirsson S.S. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res. 58:1998;123-134.
19. Kemp C.J. Hepatocarcinogenesis in p53-deficient mice. Mol. Carcinog. 12:1995;132-136.
20. Uehara T., Kashida Y., Watanabe T., Yasuhara K., Onodera H., Hirose M., Mitsumori K. Susceptibility of liver proliferative lesions in heterozygous p53 deficient CBA mice to various carcinogens. J. Vet. Med. Sci. 64:2002;551-556.
21. Iatropoulos M.J., Jeffrey A.M., Schluter G., Enzmann H.G., Williams G.M. Bioassay of mannitol and caprolactam and assessment of response to diethylnitrosamine in heterozygous p53-deficient (+/-) and wild type (+/+) mice. Arch. Toxicol. 75:2001;52-58.
22. Harvey M., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5:1993;225-229.
23. Garcia-Cao I., et al. Super p53 mice exhibit enhanced DNA damage response, are tumor resistant and age normally. Eur. Mol. Biol. Org. J. 21:2002;6225-6235.
24. Boley S.E., Wong V.A., French J.E., Recio L. p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene. Toxicol. Sci. 66:2002;209-215.
25. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
26. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. Eur. Mol. Biol. Org. J. 17:1998;4657-4667.
27. Yoon H., Liyanarachchi S., Wright F.A., Davuluri R., Lockman J.C., De La Chapelle A., Pellegata N.S. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc. Natl Acad. Sci. USA. 15:2002;15.
28. Storer R.D., et al. P53+/- hemizygous knockout mouse: overview of available data. Toxicol. Pathol. 29:2001;30-50.
29. French J., Storer R.D., Donehower L.A. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol. Pathol. 29:2001;24-29.
30. Venkatachalam S., Tyner S.D., Pickering C.R., Boley S., Recio L., French J.E., Donehower L.A. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol. Pathol. 29:2001;147-154.
31. Eferl R., Ricci R., Kenner L., Zenz R., David J.P., Rath M., Wagner E.F. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 112:2003;181-192.